MentionFox
Home › funding signals › Ansa Biotechnologies
Accelerator · announced

Ansa Biotechnologies (YC W20) — Next-generation DNA synthesis using enzymes

Before you sell to, join or invest in Ansa Biotechnologies

MentionFox check on Ansa Biotechnologies: only 1 source on file so far (checked 8 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/yc-ansa-biotechnologies

Check Ansa Biotechnologies before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Ansa Biotechnologies?

Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods. Currently, DNA is manufactured via a chemical method that has remained mostly unchanged for 35 years.

Ansa Biotechnologies is a Y Combinator company in the Winter 2020 batch. Its directory entry describes it as: Next-generation DNA synthesis using enzymes. The founders listed are Dan Lin-Arlow (Founder), Sebastian Palluk (Founder) (Y Combinator directory entry, August 20, 2022).

6 more companies from YC Winter 2020 ↓

Run the free check on Ansa Biotechnologies →

Sell to companies like Ansa Biotechnologies? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Ansa Biotechnologies

New accelerator entry · 2022-08-20 · the record

Winter 2020
batch
72
people
Early
stage
United States of America
region
Open the record →

What the record says

BatchWinter 2020
Announced2022-08-20
StageEarly
StatusActive
Team size72
IndustryHealthcare
Sub-industryHealthcare -> Industrial Bio
SectorsSynthetic Biology, Biotech
RegionsUnited States of America, America / Canada, Remote, Partly Remote
BasedSan Francisco
HiringNo
Founded2018
YC group partnerJared Friedman

Pitching, partnering or investing alongside them? See who really runs and owns Ansa Biotechnologies.

Free to see. No signup.

Keep reading

More on Ansa Biotechnologies and the records around it.

Also in YC Winter 2020

Same batch, Healthcare first.

What do you want to do with Ansa Biotechnologies?

Get the full cited report on Ansa Biotechnologies

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Ansa Biotechnologies: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

In their words

Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods. Currently, DNA is manufactured via a chemical method that has remained mostly unchanged for 35 years. Our enzyme-based approach promises to dramatically accelerate innovation in biological research and biotechnology, including therapeutics, diagnostics and biomanufacturing.

Want the whole picture on Ansa Biotechnologies?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Ansa Biotechnologies: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Ansa Biotechnologies covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind Ansa Biotechnologies: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.

Sourced from the company's Y Combinator directory entry.

RSS

Tools for this story

Each opens in a new tab, filled in for Ansa Biotechnologies. With no account yet, you sign up free and land on the result.

On these startup lists

Biotech startups Manufacturing and industrial startups

Share this page

Is this your company?

Share the news. Sharing needs no account.

Ansa Biotechnologies: Accepted into Y Combinator Winter 2020
Share on LinkedIn Share on X Download image

Cite this page

Permanent URL: https://mentionfox.com/funding/yc-ansa-biotechnologies
Last updated 2026-11-08
Primary record: Y Combinator directory entry
Ansa Biotechnologies (YC W20) — Next-generation DNA synthesis using enzymes. MentionFox, 2026-11-08. https://mentionfox.com/funding/yc-ansa-biotechnologies